Published 12 Sep 2023

Qure.ai receives 510(k) FDA clearance for its Chest X-ray solution for Pneumothorax and Pleural Effusion, Elevating ICU and ER Care Pathways

SHARE

https://cms.qure.ai

Back

Qure.ai's qXR-PTX-PE is a radiological computer-assisted triage and notification software that analyzes adult chest X-ray images for the presence of pre-specified suspected critical findings (pleural effusion and/or pneumothorax).
Qure.ai, a leading innovator in medical imaging AI, announces a pivotal 510(k) FDA clearance for its AI-enabled chest X-ray solution – qXR, under two critical findings. Qure’s qXR has now been cleared to triage pneumothorax (PTX) and pleural effusion (PE), which present severe challenges in emergency rooms and intensive care units (ICUs). The newest clearance is an addition to Qure’s existing FDA-cleared product portfolio that includes qXR-BT for breathing tube placement, qER for emergency room head CT scans, and qER-Quant for head CT quantification software.  
qXR has shown exemplary clinical accuracy in triaging pneumothorax (PTX), a condition where air collects in the pleural space, causing the lung to collapse. On the other hand, Pleura Effusion (PE) is where fluid accumulates in the pleural cavity. Performance evaluations reveal that qXR-PTX-PE excels in providing rapid passive notifications, taking an average of 10 seconds to alert healthcare professionals. This impressive speed positions qXR-PTX-PE as an indispensable medical tool designed to inform specialists promptly, especially in critical settings like ICUs and emergency rooms, and to complement the expertise of our trained medical professionals. Utilizing a globally sourced training dataset, qXR integrates into the existing standard of care workflow and serves as a passive notification system for worklist prioritization.  
The 510(k) summary explaining qXR-PTX-PE’s performance and clinical benefits is publicly available here in FDA’s database

Authors

Share this publication